Given the broad adverse prognostic impact of KRAS mutation in NSCLC, targeting of HIF1A-As2 and/or MYC by effective small-molecule compound inhibitors or agents holds potent therapeutic potential in treating KRAS-driven NSCLC. Here, MYC is linked to non-small cell lung carcinoma.